Feedback
European Shorting
My Portfolios
Browse Gurus
Print
Email
Geron Corp. has a market cap of $563.3 million; its shares were traded at around $5.69 with and P/S ratio of 326.4. Geron Corp. had an annual average earning growth of 3.4% over the past 5 years.GERN is in the portfolios of Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jean-Marie Eveillard of First Eagle Investment Management, LLC.
Highlight of Business Operations: On August 17, 2010, we issued to Hongene Biotechnology Limited (Hongene) 114,957 shares of our common stock in a private placement as consideration for an addendum agreement to a master manufacturing agreement pursuant to which Hongene is making certain raw materials for us intended to be used for the manufacture of a drug product for use in human clinical trials. The fair value of the common stock of $599,000 was recorded as a prepaid asset and will be amortized to research and development expense in connection with the receipt of the proper materials. As of September 30, 2010, $599,000 remained as a prepaid asset which is expected to be expensed over the next six months.
On August 17, 2010, we issued to Samchully Pharm. Co., Ltd. (Samchully) 115,779 shares of our common stock in a private placement as consideration for an addendum agreement to a master manufacturing agreement pursuant to which Samchully is making certain raw materials for us intended to be used for the manufacture of a drug product for use in human clinical trials. The fair value of the common stock of $603,000 was recorded as a prepaid asset and will be amortized to research and development expense in connection with the receipt of the proper materials. As of September 30, 2010, $603,000 remained as a prepaid asset which is expected to be expensed over the next six months.
On August 17, 2010, we issued to MPI Research, Inc. (MPI) 158,912 shares of our common stock in a private placement as consideration for two amendments to a master agreement under which MPI has provided and will continue to provide certain preclinical services in support of our clinical programs. The fair value of the common stock of $828,000 was recorded as a prepaid asset and is being amortized to research and development expense on a pro-rata basis as services are performed. As of September 30, 2010, $349,000 remained as a prepaid asset which is expected to be expensed over the next six months.
On August 17, 2010, we issued to ReSearch Pharmaceutical Services, Inc. (RPS) 281,426 shares of our common stock in a private placement as consideration for a project agreement to a master agreement under which RPS is providing certain services to us in support of our clinical programs. The fair value of the common stock of $1,466,000 was recorded as a prepaid asset and will be amortized to research and development expense on a pro-rata basis as services are performed. As of September 30, 2010, $1,466,000 remained as a prepaid asset which is expected to be expensed over the next six months.
Read the The complete Report
Subscribe RSS
RSS